Kidane, M.; Hoffman, R. M.; Wolfe-Demarco, J. K.; Huang, T.-Y.; Teng, C.-L.; Gonzalez Lira, L. M.; Lin-Jones, J.; Pallares, G.; Lamerdin, J. E.; Servant, N. B.; Lee, C.-Y.; Yang, C.-T.; Bernatchez, J. A.

KRAS is an important oncogenic driver which is mutated in numerous cancers. Recent advances in the selective targeting of KRAS mutants via small molecule inhibitors and targeted protein degraders have generated an increase in research activity in this area in recent years. As such, there is a need for new assay platforms to profile next generation inhibitors which improve on the potency and selectivity of existing drug candidates, while evading the emergence of resistance. Here, we describe the development of a new panel of biochemical and cell-based assays to evaluate the binding and function of known chemical entities targeting mutant KRAS. Our assay panels generated selectivity profiles and quantitative binding interaction dissociation constants for small molecules and degraders against wild type, G12C, G12D, and G12V KRAS, which were congruent with published data. These assays can be leveraged for additional mutants of interest beyond those described in this study, using both overexpressed cell-free systems and cell-based systems with endogenous protein levels.